Ovid Therapeutics Inc. (OVID): Operating Cash Flow
-$38.33M
Year ended 2025-12-31
-$54.77M
Trailing 12 months to 2026-06-30
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$38.33M | n/m | 2026-03-18, From 2025-01-01 |
| 2024-12-31 | -$55.96M | n/m | 2026-03-18, From 2024-01-01 |
| 2023-12-31 | -$45.78M | n/m | 2025-03-11, From 2023-01-01 |
| 2022-12-31 | -$55.23M | n/m | 2024-03-08, From 2022-01-01 |
| 2021-12-31 | $118.61M | n/m | 2023-03-13, From 2021-01-01 |
| 2020-12-31 | -$51.58M | n/m | 2022-03-15, From 2020-01-01 |
| 2019-12-31 | -$51.09M | n/m | 2021-03-15, From 2019-01-01 |
| 2018-12-31 | -$45.56M | n/m | 2020-03-11, From 2018-01-01 |
| 2017-12-31 | -$31.47M | n/m | 2019-03-07, From 2017-01-01 |
| 2016-12-31 | -$17.80M | n/m | 2018-03-29, From 2016-01-01 |
| 2015-12-31 | -$5.49M | n/a | 2018-03-29, From 2015-01-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| Ovid Therapeutics Inc. (OVID) | 2025-12-31 | -$38.33M | n/m |
| Whitehawk Therapeutics, Inc. (WHWK) | 2025-12-31 | -$97.43M | n/m |
| Xenon Pharmaceuticals Inc. (XENE) | 2025-12-31 | -$279.12M | n/m |
| Immunome Inc. (IMNM) | 2025-12-31 | -$190.92M | n/m |
| Adagene Inc. (ADAG) | 2025-12-31 | -$15.66M | n/m |
| Bolt Biotherapeutics, Inc. (BOLT) | 2025-12-31 | -$39.85M | n/m |
| Aclaris Therapeutics, Inc. (ACRS) | 2025-12-31 | -$47.11M | n/m |
| Coya Therapeutics, Inc. (COYA) | 2025-12-31 | -$10.74M | n/m |
| Korro Bio, Inc. (KRRO) | 2025-12-31 | -$78.56M | n/m |
Compare OVID, WHWK, XENE, IMNM side by side · Screen every company in Pharmaceutical Preparations ↗